B型慢性肝炎の世界市場レポート 2025年

B型慢性肝炎の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.2％で46億5,000万米ドルに成長します。予測期間の成長は、新興市場の拡大、政府の施策と助成金の増加、診断とスクリーニングの改善、医療支出の増加、戦略的提携とパートナーシップの増加、高齢化人口の増加、一般市民の意識向上キャンペーンの増加などに起因しています。予測期間中の主要動向としては、根治療法へのシフト、新興市場での拡大、診断とスクリーニングの強化、パートナーシップと提携、患者中心のケアの重視などが挙げられます。

B型慢性肝炎感染症の有病率の高さが、今後のB型慢性肝炎ウイルス市場の成長を牽引すると予想されます。B型肝炎は、B型肝炎ウイルス（HBV）によって引き起こされる肝臓感染症で、ワクチン接種によって予防することができます。B型肝炎感染率の上昇は、特に低・中所得国におけるワクチン接種率の低さが主要原因であり、人口のかなりの部分が無防備のままであるため、感染率の上昇につながっています。B型肝炎感染率の増加は、診断検査や治療オプションの需要を押し上げる可能性が高いです。例えば、米国の政府機関である疾病対策予防センター（CDC）が2024年6月に発表した報告書によると、世界のB型肝炎ワクチン接種率を90％に、治療へのアクセス率を80％に高めることで、2022～2050年までにB型肝炎による2,600万人の新規感染と900万人の死亡を防ぐことができるといいます。2022年だけでも、120万人のHBV感染者が新たに発生しています。その結果、B型肝炎感染の高い有病率がB型慢性肝炎ウイルス市場の成長を促進すると予想されます。

B型慢性肝炎市場の主要企業は、新規抗ウイルス療法などの技術的進歩を優先しています。これらの革新的な治療は、ウイルスの複製を阻害し、先進的デリバリーシステムを組み込むことによって、耐性株を含むウイルス感染を標的としており、B型慢性肝炎に対するbepirovirsenのように、安全性と有効性を評価する臨床検査が進行中です。例えば、2024年2月、医療製品の研究、開発、製造、販売を専門とする英国の多国籍製薬・バイオテクノロジー企業であるGSK plcは、B型慢性肝炎（CHB）に対する研究用アンチセンス・オリゴヌクレオチド（ASO）であるベピロビルセンについて、米国食品医薬品局（FDA）のファスト・トラック指定を受けた。ベピロビルセンは、B型肝炎ウイルス（HBV）のRNAを分解し、免疫系が感染をコントロールできるようにする可能性があります。この薬剤は、第IIb相検査、特にB-Clear検査とB-Sure検査において有望な結果を示しており、B型肝炎表面抗原（HBsAg）レベルの低下と持続的なウイルス抑制の達成において有効性を示しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のB型慢性肝炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のB型慢性肝炎市場：成長率分析
• 世界のB型慢性肝炎市場の実績：規模と成長、2019～2024年
• 世界のB型慢性肝炎市場の予測：規模と成長、2024～2029年、2034年
• 世界のB型慢性肝炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のB型慢性肝炎市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗ウイルス薬
• 免疫調節薬
• 世界のB型慢性肝炎市場：性別、実績と予測、2019～2024年、2024～2029年、2034年
• 男性
• 女性
• 世界のB型慢性肝炎市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• ドラッグストアと薬局
• オンラインプロバイダ
• 世界のB型慢性肝炎市場、抗ウイルス薬剤タイプ別サブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• Nucleos（T）Ide類似体（テノホビル、エンテカビル）
• インターフェロン（ペグインターフェロン）
• 世界のB型慢性肝炎市場、免疫調節薬剤タイプ別サブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫チェックポイント阻害剤
• 治療用ワクチン（開発中のHBVワクチン）

第7章 地域別・国別分析

• 世界のB型慢性肝炎市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のB型慢性肝炎市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• B型慢性肝炎市場：競合情勢
• B型慢性肝炎市場：企業プロファイル
  • Pfizer Inc.
  • F Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Bristol-Myers Squibb Company
  • Novartis AG

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Dynavax Technologies Corporation
• Gilead Sciences Inc
• Viatris Inc.
• Teva Pharmaceutical Industries Limited
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Apotex Corp
• Cipla Ltd
• Hikma Pharmaceuticals
• Lupin Pharmaceuticals Inc
• Vir BIoTechnology Inc
• VBI Vaccines Inc
• Shenzhen Hepalink Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• B型慢性肝炎市場、2029年：新たな機会を提供する国
• B型慢性肝炎市場、2029年：新たな機会を提供するセグメント
• B型慢性肝炎市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Chronic hepatitis B results from a prolonged infection with the hepatitis B virus (HBV), lasting more than six months. It can potentially cause severe liver damage, liver failure, or liver cancer. While often asymptomatic for years, it can be identified through blood tests and requires ongoing management with antiviral medications and regular monitoring.

In treating chronic hepatitis B, medications primarily consist of antivirals and immunomodulators. Antivirals are specifically designed to hinder the replication and growth of viruses. They play a crucial role in managing chronic hepatitis B by reducing the viral load in the liver and slowing the progression of liver damage.

The chronic hepatitis B market research report is one of a series of new reports from the business research company that provides chronic hepatitis B market statistics, including chronic hepatitis B industry global market size, regional shares, competitors with an chronic hepatitis B market share, detailed chronic hepatitis B market segments, market trends and opportunities, and any further data you may need to thrive in the chronic hepatitis B industry. This chronic hepatitis B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic hepatitis B market size has grown steadily in recent years. It will grow from $3.77 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to advances in antiviral therapy, growing government and NGO initiatives, improved diagnostic techniques, the rising prevalence of HIV, and increasing awareness.

The chronic hepatitis B market size is expected to see steady growth in the next few years. It will grow to $4.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to expansion in emerging markets, growing government policies and funding, improved diagnostics and screening, rising healthcare expenditure, increasing strategic collaborations and partnerships, a growing aging population, and growing public awareness campaigns. Major trends in the forecast period include a shift towards curative therapies, expansion in emerging markets, enhanced diagnostics and screening, partnerships and collaborations, and a focus on patient-centric care.

The high prevalence of chronic hepatitis B infection is expected to drive the growth of the chronic hepatitis B virus market in the future. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination. The rise in hepatitis B infection rates is largely due to low vaccination coverage, especially in low- and middle-income countries, leading to higher transmission rates as significant portions of the population remain unprotected. Increasing rates of hepatitis B infection are likely to boost demand for diagnostic tests and treatment options. For instance, according to a report published in June 2024 by the Centers for Disease Control and Prevention (CDC), a US-based government agency, increasing global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths due to hepatitis B from 2022 to 2050. In 2022 alone, there were 1.2 million new cases of HBV infection. Consequently, the high prevalence of hepatitis B infection is expected to drive growth in the chronic hepatitis B virus market.

Leading companies in the chronic hepatitis B market are prioritizing technological advancements, such as novel antiviral therapies. These innovative therapies target viral infections, including resistant strains, by inhibiting viral replication and incorporating advanced delivery systems, with ongoing clinical trials assessing their safety and efficacy, such as bepirovirsen for chronic hepatitis B. For example, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and marketing of healthcare products, received the U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for chronic hepatitis B (CHB). Bepirovirsen is designed to degrade the RNA of the hepatitis B virus (HBV), potentially enabling the immune system to regain control over the infection. The drug has shown promising results in Phase IIb trials, specifically the B-Clear and B-Sure studies, where it demonstrated efficacy in reducing hepatitis B surface antigen (HBsAg) levels and achieving sustained viral suppression.

In November 2023, GSK plc, a pharmaceutical company headquartered in the UK, acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. The acquisition includes the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug. Through this acquisition, GSK aims to enrich its portfolio and reinforce its position in the treatment of chronic hepatitis B by introducing a promising new therapy. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson based in Belgium, specializes in developing treatments for a range of serious and complex diseases, including infectious diseases such as chronic hepatitis B.

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

North America was the largest region in the chronic hepatitis B market in 2024. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic hepatitis b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic hepatitis B market consists of revenues earned by entities by providing services such as diagnostic testing, treatments, liver function monitoring, patient education, and support programs.The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic hepatitis B market also includes sales of medications, interferons, liver transplant medications, diagnostic kits, liver biopsy equipment, and HBV vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Hepatitis B Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic hepatitis b market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic hepatitis b ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic hepatitis b market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antivirals; Immune Modulators
• 2) By Gender: Male; Female
• 3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
• Subsegments:
• 1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir); Interferons (Pegylated Interferon)
• 2) By Immune Modulators: Immune Checkpoint Inhibitors; Therapeutic Vaccines (HBV Vaccines Under Development)
• Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd; Merck & Co Inc; Bristol-Myers Squibb Company; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Hepatitis B Market Characteristics

3. Chronic Hepatitis B Market Trends And Strategies

4. Chronic Hepatitis B Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Chronic Hepatitis B Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Hepatitis B PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Hepatitis B Market Growth Rate Analysis
• 5.4. Global Chronic Hepatitis B Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Hepatitis B Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Hepatitis B Total Addressable Market (TAM)

6. Chronic Hepatitis B Market Segmentation

• 6.1. Global Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antivirals
• Immune Modulators
• 6.2. Global Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Male
• Female
• 6.3. Global Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores And Retail Pharmacies
• Online Providers
• 6.4. Global Chronic Hepatitis B Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleos(T)Ide Analogs (Tenofovir, Entecavir)
• Interferons (Pegylated Interferon)
• 6.5. Global Chronic Hepatitis B Market, Sub-Segmentation Of Immune Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Therapeutic Vaccines (HBV Vaccines Under Development)

7. Chronic Hepatitis B Market Regional And Country Analysis

• 7.1. Global Chronic Hepatitis B Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Hepatitis B Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Hepatitis B Market

• 8.1. Asia-Pacific Chronic Hepatitis B Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Hepatitis B Market

• 9.1. China Chronic Hepatitis B Market Overview
• 9.2. China Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Hepatitis B Market

• 10.1. India Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Hepatitis B Market

• 11.1. Japan Chronic Hepatitis B Market Overview
• 11.2. Japan Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Hepatitis B Market

• 12.1. Australia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Hepatitis B Market

• 13.1. Indonesia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Hepatitis B Market

• 14.1. South Korea Chronic Hepatitis B Market Overview
• 14.2. South Korea Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Hepatitis B Market

• 15.1. Western Europe Chronic Hepatitis B Market Overview
• 15.2. Western Europe Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Hepatitis B Market

• 16.1. UK Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Hepatitis B Market

• 17.1. Germany Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Hepatitis B Market

• 18.1. France Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Hepatitis B Market

• 19.1. Italy Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Hepatitis B Market

• 20.1. Spain Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Hepatitis B Market

• 21.1. Eastern Europe Chronic Hepatitis B Market Overview
• 21.2. Eastern Europe Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Hepatitis B Market

• 22.1. Russia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Hepatitis B Market

• 23.1. North America Chronic Hepatitis B Market Overview
• 23.2. North America Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Hepatitis B Market

• 24.1. USA Chronic Hepatitis B Market Overview
• 24.2. USA Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Hepatitis B Market

• 25.1. Canada Chronic Hepatitis B Market Overview
• 25.2. Canada Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Hepatitis B Market

• 26.1. South America Chronic Hepatitis B Market Overview
• 26.2. South America Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Hepatitis B Market

• 27.1. Brazil Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Hepatitis B Market

• 28.1. Middle East Chronic Hepatitis B Market Overview
• 28.2. Middle East Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Hepatitis B Market

• 29.1. Africa Chronic Hepatitis B Market Overview
• 29.2. Africa Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Hepatitis B Market Competitive Landscape And Company Profiles

• 30.1. Chronic Hepatitis B Market Competitive Landscape
• 30.2. Chronic Hepatitis B Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Hepatitis B Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Dynavax Technologies Corporation
• 31.3. Gilead Sciences Inc
• 31.4. Viatris Inc.
• 31.5. Teva Pharmaceutical Industries Limited
• 31.6. Sun Pharmaceutical Industries Ltd.
• 31.7. Aurobindo Pharma Limited
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. Apotex Corp
• 31.10. Cipla Ltd
• 31.11. Hikma Pharmaceuticals
• 31.12. Lupin Pharmaceuticals Inc
• 31.13. Vir Biotechnology Inc
• 31.14. VBI Vaccines Inc
• 31.15. Shenzhen Hepalink Pharmaceutical Co. Ltd.

32. Global Chronic Hepatitis B Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Hepatitis B Market

34. Recent Developments In The Chronic Hepatitis B Market

35. Chronic Hepatitis B Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Hepatitis B Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Hepatitis B Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Hepatitis B Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer